JonathanFreemanPlehnMD
Cardiology • Keene, NYHeart Failure & Transplantation, Cardiothoracic Imaging, Cardiovascular Disease Genetics, Clinical Pharmacology
Chief Medical Officer, SignPath Pharma
Dr. Plehn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9 Sky High Way
Keene, NY 12942Phone+1 518-912-7434
Education & Training
Rush University Medical CenterFellowship, Cardiovascular Disease, 1981 - 1983
UPMC Medical EducationFellowship, Cardiovascular Disease, 1980 - 1981- UPMC Medical EducationResidency, Internal Medicine, 1978 - 1980
- UPMC Medical EducationInternship, Internal Medicine, 1977 - 1978
New York University School of MedicineClass of 1977
Certifications & Licensure
NY State Medical License 1999 - 2026
PA State Medical License 1978 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 127 citationsIs There a Relationship between Exercise Systolic Blood Pressure Response and Left Ventricular Mass?: The Framingham Heart StudyMichael S. Lauer, Daniel Levy, Keaven M. Anderson, Jonathan F. Plehn
Annals of Internal Medicine. 1992-02-01 - 12 citationsEchocardiographic assessment of LV mass in rabbits: models of pressure and volume overload hypertrophyJonathan F. Plehn, Elyse Foster, W N Grice, M. Huntington-Coats, Carl S. Apstein
The American Journal of Physiology. 1993-12-01 - 39 citationsCombinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsChristopher M. O'Connor, Mona Fiuzat, Peter E. Carson, Inder S. Anand, Jonathan F. Plehn
Plos One. 2012-10-10
Press Mentions
Medera Receives Fda Clearance for a First-in-Human Gene Therapy Trial for Heart Failure with Preserved Ejection FractionNovember 18th, 2022- Progress in Treating Chronic Kidney Disease Patients with Cardiovascular Disease: Kidney Health Initiative Develops Clinical Research RecommendationsFebruary 15th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
